- COMPOUNDS AND METHODS OF USE
-
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
- -
-
Paragraph 0653
(2021/05/07)
-
- Compounds and methods of use
-
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
- -
-
Page/Page column 433; 436; 459
(2021/08/04)
-
- Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology
-
Recent data suggest that the inhibition of arginase (ARG) has therapeutic potential for the treatment of a number of indications ranging from pulmonary and vascular disease to cancer. Thus, high demand exists for selective small molecule ARG inhibitors wi
- Lu, Min,Zhang, Hongjun,Li, Derun,Childers, Matthew,Pu, Qinglin,Palte, Rachel L.,Gathiaka, Symon,Lyons, Thomas W.,Palani, Anandan,Fan, Peter W.,Spacciapoli, Peter,Miller, J. Richard,Cho, Hyelim,Cheng, Mangeng,Chakravarthy, Kalyan,O'Neil, Jennifer,Eangoor, Padmanabhan,Beard, Adam,Kim, Hai-Young,Saurí, Josep,Gunaydin, Hakan,Sloman, David L.,Siliphaivanh, Phieng,Cumming, Jared,Fischer, Christian
-
supporting information
p. 1380 - 1388
(2021/08/06)
-
- ARGINASE INHIBITORS AND METHODS OF USE
-
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
- -
-
Page/Page column 75-76
(2019/10/04)
-
- NOVEL FERROPORTIN INHIBITORS
-
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
- -
-
Page/Page column 334; 335
(2017/05/10)
-
- PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT
-
The present invention relates to chemical compounds of formula (I) and methods for their use and preparation. In particular, the invention relates to substituted pyrazolo[3,4-d]pyrimidine based compounds which can be used in treating proliferative disorders, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
- -
-
Page/Page column 94
(2012/02/01)
-